Prefer Glenmark Pharma, Cadila Healthcare: Anu Jain

Anu Jain of IIFL Private Wealth Management told CNBC-TV18, "Glenmark Pharma is in a completely different zone because the breakout happened closer at about Rs 970-980 levels. From there it has gone up 10-12 percent and the rise is pretty vertical. The only strategy would be that you keep a stop loss at about Rs 1050. For entering at these levels it very high risk but I think given the way there is momentum, I would keep a target for a medium term of about Rs 1250. So, if you get a dip of about 4-5 percent you can probably look at making an entry if you are positively biased. However, I think the targets with which you can go over a medium term time which may not coincide with fundamentals would be Rs 1250."

"In that same sector Cadila Healthcare is looking very good. It is showing Rs 1900 odd as support. The stock has moved up about 4-5 percent from there. It is looking like in the medium term Cadila could also move up to Rs 2200," she said.

"So, that sector is catching momentum but I would probably still prefer Glenmark and Cadila."